Replimune (REPL) Prepaid Assets (2018 - 2026)
Replimune (REPL) posted Prepaid Assets of $8.6 million for Q1 2026, up 4.22% sequentially from $8.3 million in Q4 2025, and up 3.11% YoY from $8.4 million in Q1 2025.
Replimune (REPL) Prepaid Assets (2018 - 2026) Analysis & Trends
Replimune has reported Prepaid Assets for 9 years, with the latest figure at $8.6 million in Q1 2026.
- Quarterly Prepaid Assets rose 3.11% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 3.11% YoY) and the FY2026 annual result came in at $8.6 million, up 3.11% from the prior year.
- Prepaid Assets improved to $8.6 million in Q1 2026 per REPL's latest filing, from $8.3 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $8.6 million in Q1 2026 and troughed at $4.0 million in Q2 2022.
- A 5-year average of $7.3 million and a median of $8.1 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets jumped 95.42% in 2023, then slipped 20.67% in 2024.
- Over 5 years, Prepaid Assets stood at $5.6 million in 2022, then surged by 52.35% to $8.5 million in 2023, then decreased by 6.41% to $8.0 million in 2024, then advanced by 3.64% to $8.3 million in 2025, then rose by 4.22% to $8.6 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $8.6 million, $8.3 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.61 Mn |
| Dec 31, 2025 | 8.26 Mn |
| Sep 30, 2025 | 8.30 Mn |
| Jun 30, 2025 | 8.19 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 7.97 Mn |
| Sep 30, 2024 | 8.53 Mn |
| Jun 30, 2024 | 6.26 Mn |
| Mar 31, 2024 | 8.08 Mn |
| Dec 31, 2023 | 8.52 Mn |
| Sep 30, 2023 | 8.51 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 6.28 Mn |
| Dec 31, 2022 | 5.59 Mn |
| Sep 30, 2022 | 4.98 Mn |
| Jun 30, 2022 | 4.04 Mn |
| Mar 31, 2022 | 5.27 Mn |
| Dec 31, 2021 | 5.41 Mn |
| Sep 30, 2021 | 5.73 Mn |
| Jun 30, 2021 | 3.26 Mn |